EE03524B1 - Vahend diabeedi komplikatsioonide profülaktikaks ja raviks - Google Patents

Vahend diabeedi komplikatsioonide profülaktikaks ja raviks

Info

Publication number
EE03524B1
EE03524B1 EE9800208A EE9800208A EE03524B1 EE 03524 B1 EE03524 B1 EE 03524B1 EE 9800208 A EE9800208 A EE 9800208A EE 9800208 A EE9800208 A EE 9800208A EE 03524 B1 EE03524 B1 EE 03524B1
Authority
EE
Estonia
Prior art keywords
treatment
prophylaxis
present
diabetic complications
prevention
Prior art date
Application number
EE9800208A
Other languages
English (en)
Estonian (et)
Other versions
EE9800208A (et
Inventor
Hayashi Yoshiharu
Goto Nobuharu
Original Assignee
Yoshitomi Pharmaceutical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical Industries, Ltd. filed Critical Yoshitomi Pharmaceutical Industries, Ltd.
Publication of EE9800208A publication Critical patent/EE9800208A/xx
Publication of EE03524B1 publication Critical patent/EE03524B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Steroid Compounds (AREA)
EE9800208A 1995-12-27 1996-12-24 Vahend diabeedi komplikatsioonide profülaktikaks ja raviks EE03524B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34016195 1995-12-27
PCT/JP1996/003776 WO1997024333A1 (fr) 1995-12-27 1996-12-24 Composes de prevention/traitement s'appliquant aux complications de diabetes

Publications (2)

Publication Number Publication Date
EE9800208A EE9800208A (et) 1998-12-15
EE03524B1 true EE03524B1 (et) 2001-10-15

Family

ID=18334321

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800208A EE03524B1 (et) 1995-12-27 1996-12-24 Vahend diabeedi komplikatsioonide profülaktikaks ja raviks

Country Status (23)

Country Link
US (8) US6060496A (xx)
EP (2) EP0881218B1 (xx)
JP (1) JP3448869B2 (xx)
KR (2) KR100443891B1 (xx)
CN (2) CN1092645C (xx)
AT (1) ATE252563T1 (xx)
AU (1) AU716332B2 (xx)
BG (1) BG63803B1 (xx)
BR (1) BR9612316A (xx)
CA (1) CA2241856C (xx)
CZ (1) CZ294485B6 (xx)
DE (1) DE69630465T2 (xx)
EE (1) EE03524B1 (xx)
ES (1) ES2210399T3 (xx)
HK (1) HK1015777A1 (xx)
HU (1) HUP0000422A3 (xx)
IL (1) IL125104A (xx)
IS (1) IS4784A (xx)
MX (1) MX9805317A (xx)
NO (1) NO316494B1 (xx)
NZ (1) NZ324454A (xx)
RU (1) RU2173148C2 (xx)
WO (1) WO1997024333A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE252563T1 (de) * 1995-12-27 2003-11-15 Mitsubishi Pharma Corp Vorsorge-/heilmittel fur die komplikationen von diabetes
AU774471B2 (en) 1999-05-25 2004-07-01 Mitsubishi Pharma Corporation Mag expression promoters
US6482844B1 (en) * 2000-04-07 2002-11-19 Neurogen Corporation 1-benzylimidazole derivatives
CA2393877A1 (en) * 2000-11-24 2002-05-30 Toyo Shinyaku Co., Ltd. Foods containing young wheat leaf powder
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
CA2495891A1 (en) * 2002-08-29 2004-03-11 University Of Florida Research Foundation, Inc. Cox-2 mediated altered prostaglandin balance in diabetes complications
GB0314945D0 (en) * 2003-06-26 2003-07-30 Black & Decker Inc Vacuum cleaner
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
RU2741715C1 (ru) * 2020-03-20 2021-01-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ прогнозирования формирования микрососудистых осложнений сахарного диабета 2 типа

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK531479A (da) * 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS61277670A (ja) * 1985-06-03 1986-12-08 Yoshitomi Pharmaceut Ind Ltd イミダゾ−ル誘導体
US4661603A (en) * 1982-03-03 1987-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Imidazole derivatives
JPS6147477A (ja) * 1984-08-14 1986-03-07 Kowa Co 新規１，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
JPS63119425A (ja) * 1986-11-07 1988-05-24 Yoshitomi Pharmaceut Ind Ltd 免疫機能改善薬
JPS63310825A (ja) * 1987-06-03 1988-12-19 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 医薬に有用な二環式化合物のｎ−イミダゾリル誘導体
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
EP0427860A1 (en) 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
JPH037281A (ja) * 1989-03-31 1991-01-14 Kyoto Yakuhin Kogyo Kk 新規イミダゾール誘導体およびその医薬用途
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
ATE252563T1 (de) 1995-12-27 2003-11-15 Mitsubishi Pharma Corp Vorsorge-/heilmittel fur die komplikationen von diabetes

Also Published As

Publication number Publication date
BG102633A (en) 1999-09-30
IL125104A0 (en) 1999-01-26
ES2210399T3 (es) 2004-07-01
NZ324454A (en) 2000-09-29
CZ294485B6 (cs) 2005-01-12
JP3448869B2 (ja) 2003-09-22
DE69630465T2 (de) 2004-07-22
CZ9802012A3 (cs) 1998-12-16
ATE252563T1 (de) 2003-11-15
NO982988L (no) 1998-08-26
CN1159009C (zh) 2004-07-28
CN1324618A (zh) 2001-12-05
KR20040045002A (ko) 2004-05-31
HUP0000422A3 (en) 2001-06-28
RU2173148C2 (ru) 2001-09-10
US20020169194A1 (en) 2002-11-14
US20040171663A1 (en) 2004-09-02
AU1173597A (en) 1997-07-28
EE9800208A (et) 1998-12-15
EP0881218A4 (en) 1999-01-27
US20050239856A1 (en) 2005-10-27
MX9805317A (es) 1998-10-31
EP1394151A1 (en) 2004-03-03
AU716332B2 (en) 2000-02-24
US20010036957A1 (en) 2001-11-01
EP0881218A1 (en) 1998-12-02
DE69630465D1 (de) 2003-11-27
CN1092645C (zh) 2002-10-16
US6258834B1 (en) 2001-07-10
CA2241856A1 (en) 1997-07-10
HK1015777A1 (en) 1999-10-22
BR9612316A (pt) 1999-07-13
EP0881218B1 (en) 2003-10-22
CA2241856C (en) 2006-10-17
HUP0000422A2 (hu) 2001-04-28
BG63803B1 (bg) 2003-01-31
KR100471351B1 (ko) 2005-03-14
US20030130332A1 (en) 2003-07-10
KR100443891B1 (ko) 2004-10-14
WO1997024333A1 (fr) 1997-07-10
US20060148875A1 (en) 2006-07-06
IS4784A (is) 1998-06-26
NO982988D0 (no) 1998-06-26
IL125104A (en) 2002-12-01
CN1209122A (zh) 1999-02-24
NO316494B1 (no) 2004-02-02
US6060496A (en) 2000-05-09
KR19990064262A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
DE69329400T2 (de) L-Dopa Ester enthaltende Zusammensetzung
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
EE03524B1 (et) Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
HUT64318A (en) Process for production benzodpyrane derivativs and pharmaceutical preparations containing these compounds as effective substance
AU695907B2 (en) Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases
RU98113956A (ru) Средство для профилактики и лечения диабетических осложнений
RU98101105A (ru) Новое применение в медицинских целях
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
AU695190B2 (en) Substance FA-70D, process for producing the same, and uses thereof
AU4519289A (en) Medicament for the treatment of cryptosporidiosis
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
TH20329A (th) สิ่งป้องกันโรคและสิ่งหรือยาใช้รักษาโรคสำหรับบาดแผล และ/หรือการอักเสบซึ่งเกี่ยวกับตา

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20041224